News

Predictions for this year from Perry Cohen, Pharm.D., CEO of the TPG Family of Companies and Managed Healthcare Executive editorial advisory board member.

Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.

Blue Shield of California new CEO Lois Quam said she will focus on the challenges that members face with accessing healthcare.

Over 20 nonprofit veteran advocacy groups will receive $9 million over the next three years to address homelessness and mental health concerns in veterans.

A forecast for this year by Luis E. Taveras, Ph.D., senior vice president and chief information officer of Lehigh Valley Health Network.

A prediction for 2025 by Michael Meucci, president and CEO of Arcadia.

A prediction for this year from Jason Spangler, M.D., M.P.H., CEO, Center for Innovation & Value Research.

A new, first-of-its-kind study found that these symptoms occur particularly during the late menopause transition and post-menopause.

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice yearly investigational pre-exposure prophylaxis (PrEP) injection.

Modern research shows women’s health issues go beyond reproductive health and highlight women’s elevated risk for autoimmune and cardiovascular disease – among other conditions.

Here’s what you missed this week on Managed Healthcare Executive.

Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

The year's top conference coverage item shares the effects of "Ozempic Bod" and "Ozempic Face," as presented at the annual American Academy of Ophthalmology meeting in Chicago.

A systematic review and meta-analysis found some supporting evidence for transdermal anti-inflammatory patches, but the results might be described as, well, patchy.

Check out this list of the top five biologics articles posted on Managed Healthcare Executive this year!

2024's top podcast episodes includes a conversation with Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits.

Take a look at this year’s top articles — one showcasing enhanced weight loss through Semaglutide use in post-menopausal women on hormonal therapy.

This year’s top dermatology posts on Managed Healthcare Executive include stories about Gen Z sunscreen trends and increasing incidences of ringworm and jock itch.

Here are the top performing articles about obesity published this year on Managed Healthcare Executive.

One of this year's top articles on cost and coverage highlights that the average American can afford a maximum of $97 in out-of-pocket healthcare expenses.

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain medicine that might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.

Cardiomyopathies currently have no cures, but many of these disorders are prime candidates for gene therapies.

Check out this list of the top five articles posted on Formulary Watch this year!

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines being developed for other diseases outside of COVID-19.

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 shortage.

Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.

Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 fewer breathing interruptions per hour.

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older.

Here’s what you missed this week on Managed Healthcare Executive.